Q2 2019 13F Holders as of 6/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
14.4M
-
Number of holders
-
163
-
Total 13F shares, excl. options
-
14M
-
Shares change
-
+774K
-
Total reported value, excl. options
-
$570M
-
Value change
-
+$37.4M
-
Put/Call ratio
-
0.2
-
Number of buys
-
86
-
Number of sells
-
-67
-
Price
-
$40.62
Significant Holders of Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) as of Q2 2019
191 filings reported holding ANIK - Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share as of Q2 2019.
Anika Therapeutics, Inc. - Common Stock, par value $0.01 per share (ANIK) has 163 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14M shares
of 14.4M outstanding shares and own 97.23% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.16M shares), KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC (1.63M shares), DIMENSIONAL FUND ADVISORS LP (1.05M shares), AMERIPRISE FINANCIAL INC (1M shares), VANGUARD GROUP INC (916K shares), STATE STREET CORP (785K shares), RENAISSANCE TECHNOLOGIES LLC (444K shares), D. E. Shaw & Co., Inc. (413K shares), BTIM Corp. (371K shares), and MILLENNIUM MANAGEMENT LLC (289K shares).
This table shows the top 163 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.